Overview
Drug discovery has historically centered around a relatively small subset of “druggable” targets. But, in the race to be first-in-class, multiple companies pursue the same targets despite overcrowded markets. This means that to gain market share, later entrants will need to be the “best-in-class.” Now, data and analytics provide a better way to identify potential targets.
In this eBook, we explore options and offer data-driven perspectives for how companies can take a fresh approach to identifying potential drug targets.